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Aim: Vitamin D level could be related to blood pressure and cardiovascular health. However, the direct suppressor effect of vitamin D
on vascular contraction has not yet been explored. Therefore, the effects of alfacalcidol (1α-hydroxyvitamin D3) and calcitriol (1α,25dihydroxyvitamin D3) on contractions induced by phenylephrine (10–8 to 10–5 M) in mice aorta were investigated.
Materials and methods: Arterial rings were suspended in isolated organ chambers filled with Krebs bicarbonate solution gassed with
95% O2 and 5% CO2 maintained at 37 °C. Tissue responses were recorded isometrically with a force transducer and displayed on
an acquisition system. Alfacalcidol and calcitriol were applied on phenylephrine-induced active tone. Furthermore, aortic rings were
preincubated with alfacalcidol and calcitriol and thereafter contracted with phenylephrine. Incubation studies were conducted by
endothelium removal and in the presence of L-nitro-arginine methyl ester (L-NAME).
Results: Phenylephrine-induced active tones were significantly suppressed by alfacalcidol (P < 0.05 and P < 0.01) and calcitriol (both 10–5
and 10–6 M). The pEC50 values of alfacalcidol and calcitriol were 7.06 ± 0.91 and 7.13 ± 0.60, respectively. Furthermore, preincubation
of aortic rings with alfacalcidol (10–5 M) but not calcitriol (10–5 M) significantly inhibited phenylephrine-induced contractions (10–8 to
10–5 M, P < 0.05 and P < 0.001). The suppressive effect of alfacalcidol incubation disappeared with endothelium removal. Furthermore,
alfacalcidol was unable to inhibit phenylephrine-induced contractions in the presence of L-NAME, an inhibitor of nitric oxide
biosynthesis.
Conclusion: In this study we report for the first time that alfacalcidol may prevent phenylephrine-induced vasoconstriction in mice
aorta with an endothelium-dependent nitric oxide-mediated mechanism.
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1. Introduction
A growing body of evidence suggests a possible association
between vitamin D deficiency and many cardiovascular
disorders, including hypertension, peripheral vascular
disease, diabetes mellitus, metabolic syndrome, coronary
artery disease, and heart failure (1,2). It has been
reported that alfacalcidol treatment significantly and
moderately lowers blood pressure in hypertensive and
normotensive patients, respectively (3). However, the
underlying mechanisms still remain unclear. Recently,
some rapid nongenomic effects of hormones such as
estrogen, progesterone, testosterone, and vitamin D have
been explored beyond the classical genomic effects that
usually occur over a long period of time (4). These rapid,
nongenomic steroid actions are likely to be transmitted via
specific membrane receptors (4).
Calcitriol is a secosteroid whose genomic mechanism
of action is similar to that of other steroid hormones
* Correspondence: unisfarma@yahoo.com
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(5). Nongenomic steroid action may find applications in
various clinical areas such as cardiovascular and central
nervous disorders, electrolyte homeostasis, and infertility
(4). Accordingly, we have previously demonstrated that
testosterone could relax the human internal mammary
artery in vitro, and some cardiovascular risk factors
modulate the degree of this relaxation (6,7).
Vitamin D derivatives acutely reduce endotheliumdependent contractions in the aorta of the spontaneously
hypertensive rat (8). The vitamin D receptor, a member of
the steroid/thyroid hormone nuclear receptor superfamily,
is responsible for most of the biological activities of
vitamin D in the body (9). In addition, the presence of the
vitamin D receptor in endothelial cells has been reported
(10). Furthermore, annexin II, the expression of which
has been demonstrated in endothelial cells (11,12), has
been suggested as a membrane receptor for rapid actions
of calcitriol (13). These rapid actions include a variety of
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signal transduction systems including Ca2+ influx; release
of Ca2+ from intracellular stores; modulation of adenylate
cyclase, phospholipase C, and protein kinase activities; and
changes in the phosphorylation status of cellular proteins
(14). However, knowledge about the nongenomic action of
another vitamin D form, alfacalcidol, is limited.
Renovascular diseases and chronic kidney disease
(CKD) are secondary causes of hypertension. The issue of
sympathetic overactivity in CKD has been the topic of welldocumented reviews (15,16). It has been shown that oral
administration of alfacalcidol for predialysis CKD patients
is associated with reduced risk for cardiovascular diseases
(17). Several mechanisms of action of vitamin D in
hypertensive vascular disease have been proposed, such as
an increase in intracellular Ca2+ leading to decreased renin
activity, calcitriol suppression of the renin promoter gene,
and alteration of the sensitivity of vascular smooth muscle
cells (1). However, direct actions of vitamin D on vascular
tissues have not been well documented. Therefore, in the
present study we aimed to explore whether alfacalcidol
and calcitriol have any direct effects on precontracted mice
aorta. For that reason, we tested the effects of 2 vitamin
D forms, alfacalcidol and calcitriol, on mouse aortic ring
contractions due to α1 receptor agonist phenylephrine.
Any possible contribution of the endothelial integrity to
the effects of vitamin D was also tested.
2. Materials and methods
2.1. Animals
Male BALB/c mice weighing 35–40 g were obtained from
the Experimental Medicine Unit of the Mersin University
Medical Faculty. The mice were caged separately under
a 12-h light/12-h dark photoperiod and a constant
temperature (23 ± 1 °C) and they received standard mice
chow ad libitum. The study was performed in accordance
with the Guide for the Care and Use of Laboratory Animals
of the Experimental Medicine Unit of the Medical Faculty
of Mersin University.
2.2. Drugs and chemicals
Phenylephrine, potassium chloride, carbachol, Nω-nitroL-arginine methyl ester (L-NAME), alfacalcidol, and
calcitriol were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). The alfacalcidol and calcitriol were
dissolved in ethanol and the other chemicals were in
distilled water.
2.3. Tissue preparation
The mice were killed by a blow to the head and
exsanguinated. The aorta was immediately isolated
and adherent tissues were carefully removed in a petri
dish containing Krebs solution (composition in mM:
NaCl 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, NaHCO3 25,
KH2PO4 1.2, glucose 11, and Na2EDTA 0.01). Arterial

ring segments (approximately 3 mm wide) were prepared
using fine scissors, keeping the endothelium intact. In
some experiments, the endothelium was gently damaged
in order to evaluate endothelial contribution to vitamin D
action.
2.4. Experimental procedure
The aortal rings were suspended in organ baths filled
with Krebs solution (37 °C) and gassed with 95% O2 and
5% CO2 under 0.5 g of initial tension. Tissue responses
were recorded isometrically with a force transducer
(COMMAT, Ankara, Turkey) and displayed on a Biopac
acquisition system (Biopac Systems, Goleta, CA, USA).
The vessels were allowed to equilibrate at optimum resting
tensions for 60 min before experiments were carried out,
during which time the bath was replaced with fresh Krebs
solution every 20 min. Following equilibration, the arterial
rings were contracted using 80 mM KCl. After a steady
state of contraction was obtained, the rings were washed
and allowed to rest for 45 min more. Thereafter, the rings
were contracted using phenylephrine (10–5 M) and relaxed
with carbachol (10–5 M) to test the endothelial integrity. In
all of the performed experiments, the final concentration
of ethanol in the organ baths did not exceed 0.02%, which
had no effect by itself (data not shown).
2.5. Observation of alfacalcidol administration on
phenylephrine-induced active tone
After the above-mentioned procedure was conducted, a
vehicle (ethanol), alfacalcidol, or calcitriol (each at 10–8,
10–7, 10–6, and 10–5 M) was added on aortic rings that
had been precontracted with phenylephrine (10–5 M).
Arterial tones were monitored for 1 h, and at the end of
each 15 min period, the vascular tones were obtained
and expressed as percentages of phenylephrine-induced
contractions (0-min value). Each arterial segment was
used to obtain a response from only one concentration of
vehicle, alfacalcidol, or calcitriol.
2.6. Alfacalcidol and calcitriol incubation studies
Intact endothelium or mechanically damaged arterial
rings were incubated with alfacalcidol (10–5 M), calcitriol
(10–5 M), or their vehicle ethanol (0.02%) for 1 h. Following
that, the tissues were contracted with phenylephrine (10–8
to 10–5 M). Contractile responses to the phenylephrine
were shown as a percentage of 80 mM KCl-induced
contractions. Endothelial integrity was tested with
relaxation to carbachol (10–5 M).
2.7. Studies with L-NAME
While the control group was incubated with L-NAME
(2 × 10–4 M) plus ethanol (incubation period of 1 h), the
experiment group was incubated with L-NAME (2 × 10–4
M) plus alfacalcidol (10–5 M).
2.8. Statistical analyses
Arterial tones obtained after 15, 30, 45, and 60 min of
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vehicle, alfacalcidol, and calcitriol administration were
expressed as percent of phenylephrine-induced tone (0min value regarded as 100%). For the incubation studies,
the phenylephrine-induced contractions were expressed
as a percent of 80 mM KCl-induced tone and shown as
mean ± standard error of the mean (SEM). For statistical
analysis, one-way analysis of variance (ANOVA) followed
by the Bonferroni post hoc test or Student’s t-test, if
appropriate, was used. P-values of less than 0.05 were
considered significant.
3. Results
3.1. Effect of alfacalcidol and calcitriol on phenylephrineinduced active tone
Figures 1A–1F show original tracings of phenylephrine
precontracted and phenylephrine-induced contractions
of mice aorta. In the control group there was an increase
in phenylephrine-induced active tone at the end of 1 h of
observation (Figure 1A). Alfacalcidol (10–5 to 10–6 M) and

calcitriol (10–5 to 10–6 M) significantly decreased or relaxed
phenylephrine-induced (10–5 M) active tone in mice aorta
(Figures 1B, 1C, and 2A, P < 0.05). The relaxations occurred
slowly (Figures 1B and 1C). The most appropriate point
to calculate alfacalcidol and calcitriol pEC50 values was
at 30 min after application, due to statistical significance
(Figures 2A and 2B). The pEC50 values for the alfacalcidol
and calcitriol groups at 30 min after application were 7.06
± 0.91 and 7.13 ± 0.60, respectively.
3.2. Effect of alfacalcidol and calcitriol incubation on
phenylephrine-induced contractions
Preincubation of aortal rings with alfacalcidol (10–5
M) significantly inhibited the phenylephrine-induced
contractions (10–8 to 10–5 M, P < 0.05 and P < 0.001)
(Figures 1D, 1E, and 3A). The Emax values obtained with
10–5 M phenylephrine as a percentage of 80 mM KClinduced tone were 130.83 ± 3.77 (n = 6) and 77.78 ± 9.25
(n = 5) for the control and alfacalcidol groups, respectively.
To evaluate whether alfacalcidol could be converted
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Figure 1. (A), (B), and (C) are original tracings of phenylephrine-precontracted (10–5 M) mice aortal rings showing the effect of the
vehicle (0.02% ethanol), alfacalcidol (10–5 M), and calcitriol (10–5 M), respectively. Alfacalcidol and calcitriol significantly decreased or
relaxed phenylephrine-induced (10–5–10–6 M) active tone. (D), (E), and (F) are original tracings of phenylephrine-induced contractions
after 1 h of exposure to the vehicle, alfacalcidol, and calcitriol, respectively. The rings were contracted with 80 mM KCl, incubated with
the vehicle, alfacalcidol (10–5 M), or calcitriol (10–5 M), and thereafter contracted with phenylephrine (10–8 to 10–5 M). Only alfacalcidol
significantly suppressed phenylephrine-induced contractions. Phe = phenylephrine.
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Figure 2. The effect of alfacalcidol and calcitriol on phenylephrine-induced contractions during the 1-h period after vitamin D
application. Alfacalcidol (A) and calcitriol (B) significantly reduced the phenylephrine-induced tone of the arterial rings. After the rings
were contracted with phenylephrine (10–5 M), alfacalcidol (10–5 to 10–8 M), calcitriol (10–5 to 10–8 M), or the vehicle (ethanol) were added
to the organ bath. Thereafter, at the end of 15, 30, 45, and 60 min, the phenylephrine-induced tones were obtained and expressed as a
percentage of phenylephrine-induced contractions (0-min value). For statistical analysis, Student’s t-test was used and data are shown
as the mean ± SEM of 4–8 observations. * P < 0.05, ** P < 0.01.

into its active form, calcitriol, and thereafter produce
its inhibitory effect, we also preincubated the rings with
calcitriol. However, calcitriol incubation (10–5 M) did not
suppress phenylephrine-induced contractions (10–8 to 10–5
M) (Figures 1F and 3B). The Emax values obtained with 10–5
M phenylephrine as a percentage of 80 mM KCl-induced
tone were 131.32 ± 26.42 (n = 10) and 122.59 ± 28.01 (n =
8) for the control and calcitriol groups, respectively.

3.3. Effect of endothelium removal on suppression of
phenylephrine-induced contraction with alfacalcidol
preincubation
In arteries with mechanically destroyed endothelium,
alfacalcidol (10–5 M) was unable to inhibit the
phenylephrine-induced contractions (10–8 to 10–5 M),
indicating that the endothelium has a role in the inhibitory
effect of alfacalcidol (Figure 4). In the alfacalcidol
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Figure 4. The effect of alfacalcidol incubation on arteries with
mechanically destroyed endothelium. Alfacalcidol was unable
to reduce phenylephrine-induced contractions in the absence of
endothelium. The aortic rings were incubated with alfacalcidol
(10–5 M) or its vehicle (0.02% ethanol in the organ bath) for 1
h and thereafter contractions due to phenylephrine (10–8 to 10–5
M) were obtained. Phenylephrine-induced contractions were
expressed as a percentage of 80 mM KCl-induced contractions.
(-) E = endothelium mechanically destroyed, AD = alfacalcidol.
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Figure 3. The effect of alfacalcidol (A) and calcitriol (B)
incubation on phenylephrine-induced contractions. The aortic
rings were incubated with alfacalcidol (10–5 M), calcitriol,
or their vehicle (0.02% ethanol in the organ bath) for 1 h and
thereafter contractions due to phenylephrine (10–8 to 10–5 M)
were obtained. Alfacalcidol significantly reduced phenylephrineinduced contractions, but calcitriol did not. Phenylephrineinduced contractions were expressed as a percentage of 80 mM
KCl-induced contractions. For statistical analysis, one-way
ANOVA followed by a Bonferroni post hoc test were used and
data are shown as the mean ± SEM of 5–10 observations. *P <
0.05, ***P < 0.001.

preincubated group, there was a slight but not significant
increase in the phenylephrine-induced contractions.
The Emax values obtained with 10–5 M phenylephrine as
a percentage of 80 mM KCl-induced tone were 139.11 ±
18.52 (n = 5) and 158.89 ± 22.09 (n = 8) for the control and
alfacalcidol groups, respectively.
3.4. Effect of L-NAME incubation on alfacalcidolmediated
inhibition
of
phenylephrine-induced
contractions
The application of L-NAME (2 × 10–4 M) to the organ bath
gradually increased the resting tension of the arteries,
which was not significantly different between the control
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Figure 5. The effect of L-NAME incubation on alfacalcidolmediated inhibition of phenylephrine-induced contractions.
In the presence of L-NAME (2 × 10-4 M), a NOS inhibitor,
alfacalcidol was unable to inhibit phenylephrine-induced
contractions. The aortic rings were incubated with alfacalcidol
(10–5 M) plus L-NAME, or its vehicle (0.02% ethanol in the organ
bath) plus L-NAME, for 1 h; thereafter, contractions due to
phenylephrine (10–8 to 10–5 M) were obtained. AD = alfacalcidol.

and alfacalcidol groups. With the presence of L-NAME
(2 × 10–4 M), alfacalcidol (10–5 M) was unable to inhibit
the phenylephrine-induced contractions (10–8–10–5 M),
indicating that nitric oxide (NO) has a role in the inhibitory
effect of alfacalcidol (Figure 5). The Emax values obtained
with 10–5 M phenylephrine as a percentage of 80 mM KClinduced tone were 102.21 ± 19.02 (n = 5) and 102.69 ± 8.32
(n = 5) for the control and alfacalcidol groups, respectively.
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4. Discussion
The present study is the first to report that alfacalcidol
suppresses phenylephrine-induced vascular contraction.
Calcitriol suppressed or relaxed when applied to
arteries precontracted by phenylephrine; however, its
preincubation did not suppress contractions induced
by the α1 agonist. Interestingly, endothelium removal
prevented the suppressor effect of alfacalcidol, indicating
the role of this vessel layer. Furthermore, the nitric oxide
synthase (NOS) inhibitor L-NAME also abolished the
suppressor effect of alfacalcidol, suggesting that this
vasodilatation could be NO-mediated.
Increased sympathetic nerve activity is a major
actor in the development of essential hypertension
(18,19). Phenylephrine is a sympathomimetic agent
and increases blood pressure via selective α1-adrenergic
receptor stimulation. The relaxant effects of hormones,
which are generally observed in high doses that exceed the
physiological concentrations, are slow to develop when
compared to other potent relaxants but still rapid in respect
to the genomic effects (6,20). The observed suppressive or
relaxant effect of alfacalcidol on phenylephrine-induced
active tone was a slowly developing effect. However, the
suppression of phenylephrine-induced contractions was
more pronounced when the aortic rings were preincubated
with alfacalcidol.
In healthy individuals, vitamin D derived from
nutritional sources or produced in the skin is
converted to 25-hydroxyvitamin D in the liver and
then to 1,25-dihydroxyvitamin D in the kidney by
25-α-hydroxylase and 1-α-hydroxylase, respectively.
Vitamin D receptors and 1-α-hydroxylase, which convert
vitamin D into the hormonal 1,25-dihydroxyvitamin D
form, are present in many tissues, including endothelial
cells (10). However, the presence of 25-α-hydroxylase
in endothelial cells has not yet been reported. Vascular
endothelial cells are known to harbor the CYP27A gene
product (21), whose enzyme is thought to be responsible
for 25-hydroxylation of vitamin D3 (22). CYP27A1,
however, has a low affinity for vitamin D, does not
25-hydroxylate vitamin D, and, when mutated, results in
cerebrotendinous xanthomatosis, not rickets (23). In vitro,
many nonrenal tissues, including bone, placenta, prostate,
keratinocytes, macrophages, T-lymphocytes, dendritic
cells, and several cancer cells, can enzymatically convert
25-hydroxyvitamin D to 1α,25-dihydroxyvitamin D (23).
Based on our findings, alfacalcidol exerted its suppressive
effect in the mouse aorta without converting to calcitriol
because the incubation with calcitriol did not decrease
phenylephrine-induced contractions.
Although the beneficial effect of vitamin
D supplementation on hypertension has been reported
(24), another study also reported that it might protect

against cardiovascular disease but involve some
mechanisms other than blood pressure (25). The
ineffectiveness of calcitriol preincubation to suppress
phenylephrine-induced contraction is in accordance
with the findings of Wong et al. (8). Further investigation
is needed to explain the discrepancy observed with the
application procedure of calcitriol, i.e. with preincubation
and after the active tone.
Low concentrations of vitamin D have been linked
to the pathogenesis of several chronic diseases with
cardiovascular risk factors, such as hypertension, heart
failure, atherosclerosis, and peripheral arterial disease
(1,2,26). Moreover, it has been reported that vitamin D
analogs and supplements may potentially be agents for
controlling renin production and blood pressure (27).
However, little is known about the mechanism of action of
vitamin D regarding cardiovascular effect when compared
to other steroids such as testosterone, estrogen, and
progesterone.
The nongenomic vascular effects of sex hormones
include both endothelium-dependent and endotheliumindependent mechanisms involving direct effects on
vascular smooth muscle (20). Sex steroid hormones
(estrogen and testosterone) increase the production and
release of endothelium-derived nitric oxide in both men
and women (28). Since vitamin D replacement in deficient
subjects significantly improved flow-mediated dilatation of
the brachial artery, Tarcin et al. (29) suggested that vitamin
D plays a role in endothelial function. Here we report that
alfacalcidol suppresses contractions via an endotheliumdependent mechanism. As vitamin D has long been
identified to regulate Ca2+ homeostasis (30), it may modulate
Ca2+ transport in endothelial cells (8). This suppression of
contractions may occur in part via nitric oxide. According
to these findings, the idea that alfacalcidol may increase
NOS activity is in accordance with the literature (17,30).
However, endothelial NOS activity and the calcium levels in
the endothelial cells of aortic rings after vitamin D exposure
still have to be investigated.
In summary, the aim of this study was to determine the
direct acute effect of vitamin D on mice aorta. Alfacalcidol
and calcitriol inhibited or relaxed phenylephrineinduced contractions. In addition, incubation of arteries
with alfacalcidol caused a significant decrease in the α1sympathomimetic-induced contractions achieved by
phenylephrine. Alfacalcidol-induced suppression of
contractions is likely to be mediated without its conversion
to calcitriol because calcitriol preincubation itself was
ineffective. This suppressive effect might be mediated at
least in part via an endothelium-dependent NO-mediated
mechanism because the removal of the endothelium
and the NOS inhibitor, L-NAME, prevented this effect.
However, whether the mechanism of calcitriol inhibition
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of phenylephrine-induced active tone is different from
that of alfacalcidol still needs to be investigated.
In conclusion, vitamin D may be able to suppress
vasoconstriction due to phenylephrine in the mouse aorta.
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